Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 7/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.45 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.45 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 6/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | POLB | P06746 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12775400 | 1.00 | FAAH (0.47) | FAAHMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL2080366 | 1.00 | FAAH (0.47) | FAAHMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL2080370 | 1.00 | FAAH (0.47) | FAAHMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL12843890 | 0.85 | MEN1 (0.43) | FAAHMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL2082411 | 0.85 | FAAH (0.47) | FAAHMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL12775395 | 0.85 | FAAH (0.47) | FAAHMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL2082431 | 0.85 | FAAH (0.47) | FAAHMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL2082413 | 0.85 | FAAH (0.47) | FAAHMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL12449320 | 0.75 | FAAH (0.47) | FAAHMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL2335343 | 0.75 | KMT2A (0.43) | FAAHMEN1KMT2ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902237-B2 | nuclear receptor activity modulators; 4-(ethylamino)-3-{[(2Z,5Z)-5-{[methyl(phenyl)amino]methylidene}-4-oxo-3-(phenylmethyl)-1,3-thiazolidin-2-ylidene]amino}benzonitrile; diseases or disorders affected by abnormal cholesterol, triglyceride, or bile acid levels | EXELIXIS, INC. (US) | 2011-03-08 | — | — | US | claimed |
| US-20080132519-A1 | Heterocyclic Compounds As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-06-05 | — | — | US | claimed |
| US-7902237-B2 | nuclear receptor activity modulators; 4-(ethylamino)-3-{[(2Z,5Z)-5-{[methyl(phenyl)amino]methylidene}-4-oxo-3-(phenylmethyl)-1,3-thiazolidin-2-ylidene]amino}benzonitrile; diseases or disorders affected by abnormal cholesterol, triglyceride, or bile acid levels | EXELIXIS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902237-B2 | nuclear receptor activity modulators; 4-(ethylamino)-3-{[(2Z,5Z)-5-{[methyl(phenyl)amino]methylidene}-4-oxo-3-(phenylmethyl)-1,3-thiazolidin-2-ylidene]amino}benzonitrile; diseases or disorders affected by abnormal cholesterol, triglyceride, or bile acid levels | EXELIXIS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902237-B2 | nuclear receptor activity modulators; 4-(ethylamino)-3-{[(2Z,5Z)-5-{[methyl(phenyl)amino]methylidene}-4-oxo-3-(phenylmethyl)-1,3-thiazolidin-2-ylidene]amino}benzonitrile; diseases or disorders affected by abnormal cholesterol, triglyceride, or bile acid levels | EXELIXIS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080132519-A1 | Heterocyclic Compounds As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132519-A1 | Heterocyclic Compounds As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132519-A1 | Heterocyclic Compounds As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132519-A1 | Heterocyclic Compounds As Pharmaceutical Agents | CNR1, CNR2, TACR2 | FAAH 413/4885MEN1 2621/4885KMT2A 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.